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The epidermal growth factor receptor (EGFR) is a member of the erbB family of tyrosine kinase receptors (RTK). The EGFR is
involved in cell proliferation, metastasis and angiogenesis, and is expressed in a large proportion of epithelial tumours. The two main
classes of EGFR inhibitors in clinical trials are the RTK inhibitors and the monoclonal antibodies. The clinical development of EGFR
inhibitors has introduced new challenges to the design of phase I, II, and III trials. Both classes of agents can be safely administered at
doses sufficient to inhibit the EGFR system. Receptor tyrosine kinase inhibitors have been extensively evaluated in non-small-cell lung
cancer. In this setting, gefitinib has demonstrated activity in patients who fail initial chemotherapy. Monoclonal antibodies have been
developed in combination with cytotoxic chemotherapy in several tumour types, most notably colorectal and head and neck cancer.
The preliminary results suggest an increase in response rate and time to progression with the combination of cetuximab and
chemotherapy in both disease models. Future issues in the development of EGFR inhibitors include the identification of biologic
predictors of response, combination with other targeted agents, and their utilisation in earlier stage malignancies.
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The epidermal growth factor receptor (EGFR; erbB1) is a member
of the tyrosine kinase receptor family, which includes HER2/neu
(erbB2), erbB3, and erbB4 (Olayioye et al, 2000; Yarden, 2001). The
ErbB receptors are present at the cell surface and share a common
structure composed of an extracellular ligand-binding domain,
transmembrane segment, and an intracellular tyrosine kinase
domain (Yarden, 2001). In normal tissue, the ErbB receptors are
activated by a variety of receptor-specific ligands. The ligands
specific to the EGFR are epidermal growth factor and transforming
growth factor-a (TGF-a) (Yarden, 2001). After ligand binding, the
receptors form homo- or heterodimeric complexes activating the
tyrosine kinase domain (Olayioye et al, 2000; Yarden, 2001).
Subsequently, intracellular proteins involved in signalling path-
ways are phosphorylated and activated, resulting in modulation of
gene transcription (Schlessinger, 2000).
The function of the ErbB receptors is dysregulated in several
malignant disorders including among others lung, breast, colo-
rectal, squamous cell cancer of the head and neck (SCCHN), and
prostrate cancer (Salomon et al, 1995; Mendelsohn, 2002).
Mechanisms involved in the activation of the ErbB receptors
include: (1) receptor overexpression (Hirsch et al, 2003), (2)
mutant receptors resulting in ligand-independent activation
(Hirsch et al, 2003; Moscatello et al, 1995), (3) autocrine activation
by overproduction of ligand (Prenzel et al, 1999) or (4) ligand-
independent activation through other receptor systems such as the
urokinase plasminogen receptor (Liu et al, 2002). Activation of the
EGFR is involved in malignant transformation and tumour growth
through the inhibition of apoptosis, cellular proliferation, promo-
tion of angiogenesis, and metastasis.
At the cellular level, three major signalling pathways mediate the
downstream effects of EGFR activation (Figure 1). The first
pathway involves the Ras-Raf-MAP kinase pathway (Lewis et al,
1998). The second pathway involves phosphatidylinositol 3-kinase
(PI-3K) and Akt (Chan et al, 1999; Vivanco and Sawyers, 2002).
The third pathway involves the stress-activated protein kinase
pathway, involving Jak/Stat and protein kinase C (Sato et al, 1983;
Boudny and Kovarik, 2002).
STRATEGIES TARGETING THE EGFR PATHWAY
Four strategies for targeting the EGFR are at different stages of
development. These include: (1) monoclonal antibodies against the
EGFR (Sato et al, 1983), (2) inhibition of the receptor tyrosine
kinase (RTK) domain (Lichtner et al, 2001), (3) inhibition of
receptor trafficking to the cell membrane (Yamazaki et al, 1998),
and (4) inhibition of EGFR synthesis through antisense oligonu-
cleotides (Ciardiello et al, 2001b). Only the monoclonal antibody
and RTK inhibitor class of agents have been evaluated through
phase III trials.
Monoclonal antibodies
Monoclonal antibodies bind to the extracellular domain of the
EGFR and inhibit ligand binding to the receptor (Sato et al, 1983).
After binding to the EGFR, the monoclonal antibodies induce
receptor dimerisation and downregulation. Cetuximab (IMC-C225,
Erbitux ImClone Systems Inc, New York, NY, USA), ABX-EGF
(Abgenics, San Francisco, CA, USA), and EMD 72000 are
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www.bjcancer.commonoclonal antibodies directed against the EGFR that are
currently in clinical trials. Another class of monoclonal antibodies
consists of bispecific antibodies that can bind the EGFR and an
immunologic effector cell (Negri et al, 1995; Tosi et al, 1995;
Curnow, 1997). Examples of this class of agents include M26.1,
MDX-447, and H22-EGF. These agents have shown promising
activity in early clinical trials (Negri et al, 1995; Tosi et al, 1995;
Curnow, 1997).
Receptor tyrosine kinase inhibitors
Receptor tyrosine kinase inhibitors compete with ATP for the
intracellular catalytic site of the EGFR. In contrast to the
monoclonal antibodies, this class of agents does not downregulate
the EGFR. Receptor tyrosine kinase inhibitors differ with respect to
reversibility of inhibition and specificity to the EGFR vs the other
ErbB receptors. Based on these differences, four different classes of
RTK inhibitors can be identified and these include: (1) reversible
EGFR inhibitors (e.g. gefitinib, erlonitib), (2) irreversible EGFR
inhibitors (e.g. EKB-569), (3) reversible dual-ErbB inhibitors (e.g.
GW2016), and (4) irreversible pan-ErbB inhibitors (e.g. CI-1033)
(Mendelsohn and Baselga, 2003).
Comparison of the monoclonal antibody and RTK
compounds
Both these classes of agents result in downregulation of the MAPK,
PI3K/Akt, and Jak/Stat signal transduction pathways (Bruns et al,
2000; Albanell et al, 2001). Monoclonal antibodies also down-
regulate EGFR expression, while RTKs inhibit receptor phosphor-
ylation without affecting expression. At the cellular level, EGFR
inhibitors result in cell cycle arrest at the G1 phase (Wu et al, 1995;
Busse et al, 2000), decrease tumour neovascularisation by down-
regulating expression of angiogenic mediators such as vascular
endothelial growth factor (VEGF) (Perrotte et al, 1999; Ciardiello
et al, 2001a), and promote apoptosis (Moyer et al, 1997; Liu et al,
2000). While monoclonal antibodies require an intact EGFR
ligand-binding domain to be active, the RTK inhibitors are active
against mutated forms of the EGFR.
At the clinical level, several differences between RTK inhibitors
and monoclonal antibodies exist. The RTK compounds are orally
administered while the monoclonal antibodies require intravenous
administration. While both classes of agents are associated with
acenform rash (Baselga et al, 2000, 2002), only RTK inhibitors have
been associated with gastrointestinal toxicity (Baselga et al, 2002;
Herbst et al, 2002). The preliminary results of clinical trials also
suggest different disease-specific activity for each class of agents.
For example, cetuximab (Saltz et al, 2001a, 2002) and EMD 72000
(Tewes et al, 2002) are both active in colorectal cancer, in contrast
to erlonitib (Townsley et al, 2002) and gefitinib (Seymour et al,
2002), which have failed to demonstrate activity against this
tumour type, but have shown activity against non-small-cell lung
cancer (NSCLC).
RESULTS OF THE CLINICAL TRIALS EVALUATING
THE RTK INHIBITORS
Gefitinib
In the initial phase I clinical trials, patients were treated with
escalating doses of gefitinib (50–925mgday
 1) for 14 days of a 28-
day cycle (Ranson et al, 2002; Nakagawa et al, 2003). In these trials,
the maximal tolerated dose (MTD) was 700mgday
 1. The dose-
limiting toxicities were diarrhoea and aceniform rash. Objective
responses were observed across all doses starting at the
225mgday
 1 dose, raising the possibility that inhibition of the
EGFR may be achieved at doses lower than the MTD. In order to
Figure 1 The EGFR signalling pathways. After ligand activation, the EGFR phosphorylates and activates the Ras-Raf-MAP kinase, PI-3K/Akt, and Stat/Jak
pathways. This in turn results in activation of transcription factors and modulation of the cell cycle, growth, apoptosis, and angiogenic processes.
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multicentre Phase I pharmacodynamic (PD) trials were performed
in patients with five tumour types known to express EGFR
(NSCLC, SCCHN, ovarian, colorectal, or prostate cancer) (Baselga
et al, 2002; Herbst et al, 2002). Secondary objectives were to
determine the pharmacokinetic (PK) profile, to investigate the
feasibility and sensitivity of the Functional Assessment of Cancer
Therapy (FACT) questionnaire and the seven-item Lung Cancer
Subscale (LCS) of FACT in assessing improvements in quality of
life and disease-related symptoms, respectively. Dose escalation
proceeded until the MTD (800mgday
 1) was determined.
Common adverse events were mild dose-related skin toxicity and
diarrhoea. Biologically relevant plasma concentrations were
maintained at doses X150mgday
 1, and skin biopsies demon-
strated EGFR inhibition at the same dose as well as inhibition of
the downstream signalling pathways involving MAPK, p27, and
keratinocyte proliferation index (Albanell et al, 2002). Both the
LCS and FACT questionnaires were found to be feasible and
sensitive tools with which to assess improvements in these areas.
Patients with NSCLC who had stable disease for X6 months also
had improvements or stabilisation in disease-related symptoms
(LCS scores), while those patients with disease progression had
worsened LCS scores (LoRusso et al, 2003). These trials reported
the utility of alternative end points in early clinical trials of novel,
targeted, anticancer agents.
Based on the phase I trials, two dose levels were selected for
Phase II/III studies: 250 and 500mgday
 1. The former is above the
lowest dose shown to produce biologic and antitumour activity,
thereby ensuring adequate gefitinib drug exposure. Pharmacoki-
netics from phase I trials also identified plasma levels greater than
the targeted cell line IC90 values (100ngml
 1) in 100% of patients
treated at this dose. The 500mg dose was the highest dose tolerated
by most patients on a chronic daily dosing schedule. It also
provided greater exposure than the 250mg dose.
Two large, dose-randomised, double-blind, parallel-group,
multicentre Phase II trials (IDEAL 1 and 2, Iressat Dose
Evaluation in Advanced Lung cancer) independently evaluated
the activity of 250 and 500mgday
 1 gefitinib in a combined total
of 425 patients with advanced NSCLC who failed prior chemother-
apy (Fukuoka et al, 2003; Kris et al, 2003). In both trials, fewer and
less severe side effects were observed using 250mgday
 1
compared with 500mgday
 1, while no differences in efficacy end
points (response rate, disease control rate, overall survival, and
symptom improvement) were seen between the two doses.
Response rates ranged from 9 to 19% and, overall, approximately
40% of patients experienced disease control and symptom
improvement. These two trials resulted in the recommendation
of the 250mg dose for use in further clinical trials.
Two randomised trials (INTACT 1 and 2, Iressa NSCLC Trial
Assessing Combination Treatment) evaluated the effect of
combining gefitinib and chemotherapy as first-line therapy for
NSCLC. In the first trial, 1250 patients were randomised to receive
gemcitabine and cisplatin with either placebo or gefitinib at either
250 or 500mgday
 1 (Giaccone et al, 2002). In the second trial,
1037 patients were randomised to receive carboplatin and
paclitaxel with either placebo, gefitinib 250 or 500mgday
 1
(Herbst et al, 2003). In both trials, no difference in survival,
progression-free survival or symptom control was observed
between the gefitinib/chemotherapy and the chemotherapy alone
groups. One possible interpretation for the lack of synergy between
gefitinib and cytotoxic agents is related to the G1 arrest of cells
continuously exposed to gefitinib. Human cancer xenograft models
comparing pulsatile to continuous administration of gefitinib in
combination with paclitaxel demonstrated superior tumour kill
with the pulsatile schedule (Solit et al, 2003). Based on these
preclinical data, trials designed to evaluate pulsatile administration
of gefitinib in combination with cytotoxic agents in NSCLC are
being conducted.
Cohen et al (2002) reported the results of gefitinib
(500mgday
 1) in 52 patients with recurrent SCCHN. Of the 40
response-evaluable patients, eight patients had an objective
response and 14 patients had stable disease. Phase II trials of
gefitinib in prostate (Moore et al, 2002), breast, colorectal
(Seymour et al, 2002), and gastric cancer have been reported or
are ongoing. Table 1 summarises the results of these trials.
Erlonitib
Based on the phase I trial, the MTD of erlonitib is 150mgday
 1
(Hidalgo et al, 2001). Erlotinib was evaluated in a phase II trial in
Table 1 Summary of clinical trials evaluating RTK inhibitors
Agent Disease Trial design Results
Gefitinib NSCLC
IDEAL 1 Randomised phase II trial
Second- and third-line therapy
Single-agent gefitinib at 250 and 500mgday
 1 doses
Response rate 18%
Stable disease 54%
No difference between the two arms
IDEAL 2 Randomised phase II trial
Third-line therapy
Response rate 8 8–11%
Stable disease 42%
Single-agent gefitinib at 250 and 500mgday
 1 doses No difference between the two arms
INTACT 1 Randomised phase III trial
Gemcitabine/cisplatin with or without gefitinib
No difference between the three arms. (median survival 11.1, 9.9,
and 9.9 months for placebo, 250mg, 500mg arms, respectively)
INTACT 2 Randomised phase III trial
Carboplatin/Taxol with or without gefitinib
No difference between the three arms. (median survival 9.9, 9.8,
and 8.7 months for placebo, 250mg, 500mg arms, respectively)
Prostate cancer Phase II trial in hormone refractory disease. Patients
randomised to 250 and 500mgday
 1 dose
No objective or PSA responses observed
SCCHN Phase II single-agent study Response rate 11%
Colorectal cancer Second-line therapy. Gefitinib dose 750mgday
 1 No responses
Erlonitib NSCLC Phase II trial
Second/third-line therapy
Overall response rate 12%
1-year survival 40%
Ovarian cancer Phase II trial
Previously treated patients
Overall response rate 6%
Stable disease in 20%
SCCHN Phase II trial
Previously treated patients with local or metastatic
recurrence
Overall response rate 5%
Hepatocellular
cancer
Phase II previously untreated patients Overall response 50%
Median time to progression 3.2 months
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line chemotherapy (Perez-Soler et al, 2001). The overall response
rate was 12% and the 1-year survival was 40%. Currently, erlonitib
vs placebo is being evaluated in a phase III trial in patients with
refractory NSCLC and in first-line setting with combination
chemotherapy.
Erlonitib has also been evaluated in phase II trials in ovarian
(Finkler et al, 2001), SCCHN (Senzer et al, 2001), and hepatocel-
lular carcinoma (Philip, 2004). A summary of the results and
design of the above studies is provided in Table 1.
RESULTS OF CLINICAL TRIALS EVALUATING MONO-
CLONAL ANTIBODIES AGAINST EGFR
Cetuximab
Phase I trials have established the optimal biologic dose range of
cetuximab to be 200–400mgm
 2 (Baselga et al, 2000). At this dose
range, cetuximab downregulates EGFR and inhibits downstream
signalling. The major toxicity was aceniform rash. Allergic or
anaphylactic reactions were observed in 2% of the patients.
Cetuximab has been evaluated in colorectal, SCCHN, NSCLC, and
pancreatic cancer.
In contrast to the development of RTK inhibitors, early clinical
trials with cetuximab have focused on combination therapy with
cytotoxic agents. This was based on the nonoverlapping toxicity as
well as the experiments in cell culture and human xenograft
models demonstrating the potentiation of the effects of cytotoxic
agents by cetuximab. Table 2 summarises the results of recent
trials involving monoclonal antibodies against the EGFR. In a
phase II trial, 120 patients with colorectal cancer who had
progressed on irinotecan were treated with cetuximab and
irinotecan. The observed response rate was 22.5% (Saltz et al,
2001b). A subsequent phase II trial demonstrated that the response
rate to cetuximab in a similar group of patients was 11%,
suggesting that cetuximab can modulate the mechanism of
irinotecan resistance (Saltz et al, 2002). Cunningham et al (2003)
reported on a phase III trial randomising patients with colorectal
cancer, who had progressed on irinotecan to cetuximab with or
without irinotecan. A total of 329 patients were enrolled. Response
rate (cetuximab/irinotecan 23 vs cetuximab 11%, P¼0.074) and
time to progression (cetuximab/irinotecan 4.1 months vs cetux-
imab 1.5 months, Po0.001) were significantly improved by the
combination. No significant difference in survival was observed. A
phase II trial evaluating cetuximab in patients with advanced
SCCHN refractory to platinum-based regimens has recently been
reported (Baselga et al, 2003). In all, 75 patients were enrolled in
the study. The observed response rate was 11%. A phase III trial
compared cisplatin and cetuximab to cisplatin and placebo in
patients with recurrent SCCHN previously treated with cisplatin
(Burtness et al, 2003). A total of 118 patients were enrolled in the
study. The response rates were significantly higher in the group of
patients on the combination arm (25.7 vs 10.2%, P¼0.048). There
was no significant difference with respect to median progression-
free survival and overall survival between the two arms of the
study.
Preliminary results of a randomised trial comparing cisplatin/
vinorelbine with or without cetuximab in previously untreated
patients with NSCLC have been reported (Gatzemeier et al, 2003).
In contrast to the INTACT trial design, only patients with EGFR
expressing tumours were enrolled in the study. Of the 73 patients
screened, only 65 patients (89%) expressed the EGFR. A total of 56
patients were enrolled in the study. The overall response rate was
higher in the cetuximab arm (50 vs 29%). The final results of this
study are pending.
A Phase II trial evaluating cetuximab and gemcitabine in
advanced chemo-naı ¨ve pancreatic cancer was designed
(Abbruzzese et al, 2001). In all, 41 patients were treated
with weekly cetuximab and gemcitabine. The end points were
objective response and time to progression. The overall response
rate was 51%, with 12% partial response and 39% stable
disease. Time to progression (TTP) was 12 weeks, which is longer
than the historical control with gemcitabine (median TTP 8
weeks). The Southwestern Oncology Group (SWOG) is currently
comparing gemcitabine with and without cetuximab in pancreatic
cancer.
FUTURE DIRECTIONS
Predictors of response
The advantages of defining predictors of response include:
preventing the exposure of patients to potentially harmful and/
or ineffective agents, increasing the effectiveness of therapy
through selecting a group of patients with a higher likelihood of
response, and identifying patient populations that require different
therapies. Since response to other targeted agents such as
herceptin and tamoxifen depends mainly on the level of expression
of the target, several trials have focused on defining a similar
association in the EGFR system. Saltz et al (2001a) found no
association between EGFR expression by immunohistochemistry
in colorectal cancer and response to cetuximab. Similarly, no
association was found between response to cetuximab and EGFR
expression in SCCHN (Baselga et al, 2003), response to gefitinib in
NSCLC (Bailey et al, 2003), and breast cancer (Iacobuzio-Donahue
et al, 2003).
Table 2 Summary of clinical trials evaluating cetuximab
Disease
Cytotoxic
agents Trial design Results
Colorectal
cancer
Irinotecan Phase II trial in patients progressing on irinotecan Partial response 22.5%
Stable disease 7%
Phase III trial in patients progressing on irinotecan
comparing cetuximab to the combination
Response rate (23 vs 11%), stable disease (55.5% vs 32%), and TTP
(4.1 vs 1.5 months) significantly improved by the combination
SCCHN Cisplatin Phase II trial in patients progressing on cisplatin Response rate 11%
Phase III trial in patients progressing on cisplatin comparing
cetuximab to the combination
Significant improvement in response rate but not in survival
Pancreatic
cancer
Gemcitabine Phase II trial in previously untreated patients Overall response rate 51%. Median TTP 12 weeks
NSCLC Cisplatin/
vinorelbine
Randomised trial in the first line setting Response rate 50% in the cetuximab/chemotherapy arm vs 29% in
the chemotherapy only arm
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downstream signalling pathways on the EGFR are other potential
predictors of response. For example, preclinical models suggest
that cells with mutant PTEN phosphatase resulting in EGFR-
independent activation of the Akt pathway are resistant to RTK
inhibitors (Anido et al, 2003). To define the translational worth of
these markers, a prospective trial should be designed to
incorporate an evaluation of the EGFR and the downstream
signaling pathway status pre and post treatment in order to define
the predictors of response to EGFR inhibitors. These trials will
require serial tumour biopsies, which raise ethical and financial
issues related to subjecting patients to invasive procedures. These
trials could also help in defining features present in pre-treatment
biopsies that could predict for response. An example of such a trial
is the recently reported phase I trial of EMD 72000 in patients with
colorectal cancer. In this study, only tumours with low baseline
phosphorylated Akt that was inhibited post treatment had a
response to EMD 72000. These results suggest that the Akt might
play a central role in the antitumour effects of EGFR inhibitors.
Another approach to identify predictors of response to EGFR
blockade is to utilise gene microarrays. The advantage of this
design is that it allows investigators to assay the effects of the
EGFR inhibitors on the expression of a large number of proteins.
Such trial designs would still require serial tumour biopsies.
Combination therapy involving EGFR inhibitors
As discussed previously, several recent trials have focused on
combining EGFR inhibitors with cytotoxic chemotherapy. Other
combinations at different stages of development include EGFR
inhibitors with other targeted agents, or with radiation therapy.
Cancer cells have several dysregulated and redundant pathways;
therefore, combining targeted agents may be necessary in order to
achieve the desired modulation of a cellular pathway. Combining
inhibitors of the EGFR with inhibitors acting on the downstream
signalling pathway such as MAPK or Akt could potentially result in
an improved inhibition of these pathways translating into
increased antitumour effects. These combinations are currently
being evaluated in preclinical models. Activation of the EGFR
system results in transcription of several proteins such as VEGF
and cyclooxygenase-2. Therefore, inhibiting the EGFR can down-
regulate the expression of these targets, facilitating their inhibition
by target-specific agents. The preliminary results of a phase I/II
trial evaluating bevacizumab and erlonitib in patients with NSCLC
have been recently reported (Mininberg et al, 2003). The
preliminary results indicate that both agents can be safely
administered at full dose. A phase II trial at Wayne State
University is evaluating celecoxib and gefitinib in NSCLC. Since
RTK inhibitors and monoclonal antibodies inhibit the EGFR
system by different mechanisms, their antitumour effects could
potentially be improved by combining them. Similarly, since EGFR
and ErbB2 can heterodimerise and both receptors are simulta-
neously overexpressed in several disease models, combining
herceptin with an EGFR inhibitor might be necessary to inhibit
both receptors. The results of clinical trials exploring such
combinations have not yet been reported. Cetuximab was safely
combined with radiation therapy in a phase II trial of SCCHN
(Robert et al, 2001). In all, 13 complete and two partial responses
were observed in the 16 patients enrolled in the study. Encouraged
by these results, a phase III trial of radiation with or without
cetuximab is ongoing.
Role of EGFR inhibitors in early-stage disease
Epidermal growth factor receptor inhibitors have demonstrated
significant activity in patients with metastatic NSCLC, who have
failed cytotoxic chemotherapy. These results raise the possibility of
a role for EGFR inhibitors in locally advanced NSCLC. Currently,
SWOG is conducting a randomised trial in patients with stage III
NSCLC. Patients enrolled in this study will receive definitive
chemo-radiotherapy, followed by docetaxel with subsequent
randomisation to either gefitinib or placebo. The low incidence
of toxicity associated with the EGFR inhibitors has also raised the
possibility of a potential role for these agents in the adjuvant
setting. SWOG is currently conducting a phase III trial randomis-
ing patients with stage I and II NSCLC to either gefitinib or placebo
after resection. The results of these trials will help define the role of
targeted agents after definitive treatment of early-stage and locally
advanced NSCLC.
CONCLUSION
The EGFR inhibitors have already demonstrated activity in several
advanced stage cancers including NSCLC, colorectal, and squa-
mous cell carcinomas of the SCCHN. The role of EGFR inhibitors
in early-stage disease is currently being evaluated. The preclinical
and clinical development of this class of agents has required novel
trial designs that could be incorporated into future trials involving
other novel targeted therapies.
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